Literature DB >> 17950280

Stem cells for the treatment of spinal cord injury.

Margaret Coutts1, Hans S Keirstead.   

Abstract

This article reviews stem cell-based strategies for spinal cord injury repair, and practical issues concerning their translation to the clinic. Recent progress in the stem cell field includes clinically compliant culture conditions and directed differentiation of both embryonic stem cells and somatic stem cells. We provide a brief overview of the types of stem cells under evaluation, comparing their advantages and disadvantages for use in human clinical trials. We review the practical considerations and risks that must be addressed before human treatments can begin. With a growing understanding of these practical issues, stem cell biology, and spinal cord injury pathophysiology, stem cell-based therapies are moving closer to clinical application.

Entities:  

Mesh:

Year:  2007        PMID: 17950280     DOI: 10.1016/j.expneurol.2007.09.002

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  53 in total

Review 1.  Transplantation of umbilical cord blood stem cells for treating spinal cord injury.

Authors:  Dong-Hyuk Park; Jeong-Hyun Lee; Cesario V Borlongan; Paul R Sanberg; Yong-Gu Chung; Tai-Hyoung Cho
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

2.  Stress-resistant neural stem cells positively influence regional energy metabolism after spinal cord injury in mice.

Authors:  Karsten Schwerdtfeger; Angelika E M Mautes; Christian Bernreuther; Yifang Cui; Jérôme Manville; Marcel Dihné; Simon Blank; Melitta Schachner
Journal:  J Mol Neurosci       Date:  2011-08-11       Impact factor: 3.444

3.  Glial Cell Line-Derived Neurotrophic Factor-Transfected Placenta-Derived Versus Bone Marrow-Derived Mesenchymal Cells for Treating Spinal Cord Injury.

Authors:  Yao Lu; Hui Gao; Man Zhang; Bing Chen; Huilin Yang
Journal:  Med Sci Monit       Date:  2017-04-14

Review 4.  Recent therapeutic strategies for spinal cord injury treatment: possible role of stem cells.

Authors:  D Garbossa; M Boido; M Fontanella; C Fronda; A Ducati; A Vercelli
Journal:  Neurosurg Rev       Date:  2012-04-27       Impact factor: 3.042

5.  Blocking Autophagy in Oligodendrocytes Limits Functional Recovery after Spinal Cord Injury.

Authors:  Sujata Saraswat Ohri; Andrew N Bankston; S Ashley Mullins; Yu Liu; Kariena R Andres; Jason E Beare; Russell M Howard; Darlene A Burke; Amberly S Riegler; Allison E Smith; Michal Hetman; Scott R Whittemore
Journal:  J Neurosci       Date:  2018-05-23       Impact factor: 6.167

Review 6.  Stem cell-based therapies for spinal cord injury.

Authors:  Rishi S Nandoe Tewarie; Andres Hurtado; Ronald H Bartels; Andre Grotenhuis; Martin Oudega
Journal:  J Spinal Cord Med       Date:  2009       Impact factor: 1.985

Review 7.  Oligodendrocyte fate after spinal cord injury.

Authors:  Akshata Almad; F Rezan Sahinkaya; Dana M McTigue
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

8.  Effectiveness of intense, activity-based physical therapy for individuals with spinal cord injury in promoting motor and sensory recovery: is olfactory mucosa autograft a factor?

Authors:  Cathy A Larson; Paula M Dension
Journal:  J Spinal Cord Med       Date:  2013-01       Impact factor: 1.985

9.  Transplanted astrocytes derived from BMP- or CNTF-treated glial-restricted precursors have opposite effects on recovery and allodynia after spinal cord injury.

Authors:  Jeannette E Davies; Christoph Pröschel; Ningzhe Zhang; Mark Noble; Margot Mayer-Pröschel; Stephen J A Davies
Journal:  J Biol       Date:  2008-09-19

10.  Roles of ES cell-derived gliogenic neural stem/progenitor cells in functional recovery after spinal cord injury.

Authors:  Gentaro Kumagai; Yohei Okada; Junichi Yamane; Narihito Nagoshi; Kazuya Kitamura; Masahiko Mukaino; Osahiko Tsuji; Kanehiro Fujiyoshi; Hiroyuki Katoh; Seiji Okada; Shinsuke Shibata; Yumi Matsuzaki; Satoshi Toh; Yoshiaki Toyama; Masaya Nakamura; Hideyuki Okano
Journal:  PLoS One       Date:  2009-11-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.